CPP
CORT icon

Crow Point Partners’s Corcept Therapeutics CORT Stock Holding History

Crow Point Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-23,488
Closed -$342K – 87
2019
Q3 		$342K Hold
23,488
– – 0.05% 82
2019
Q2 		$262K Hold
23,488
– – 0.04% 90
2019
Q1 		$276K Hold
23,488
– – 0.05% 87
2018
Q4 		$306K Hold
23,488
– – 0.06% 80
2018
Q3 		$329K Buy
23,488
+7,182
+44% +$100K 0.06% 110
2018
Q2 		$257K Buy
16,306
+12,951
+386% +$225K 0.05% 96
2018
Q1 		$55K Buy
3,355
+434
+15% +$8.04K 0.01% 185
2017
Q4 		$53K Buy
+2,921
New +$52.9K 0.01% 204

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Crow Point Partners's CORT Position: Q4 2019 in Review

Crow Point Partners sold out of Corcept Therapeutics (CORT) in Q4 2019, closing a stake of 23,488 shares — an estimated $342K sold.

Crow Point Partners first reported a position in CORT in Q4 2017 and held it in 8 quarters. The position peaked at $342K in Q3 2019. 205 funds tracked by Wall St. Rank hold CORT as of Q4 2019.

  • Crow Point Partners reported no remaining Corcept Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Crow Point Partners sold 23,488 Corcept Therapeutics shares in Q4 2019, an estimated $342K.
  • Crow Point Partners first reported a position in Corcept Therapeutics in Q4 2017 and held it in 8 quarters.
  • Crow Point Partners's Corcept Therapeutics position peaked at $342K in Q3 2019.
  • 205 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2019.

Based on Crow Point Partners's 13F filing for Q4 2019, filed 14 Feb 2020.